Fig. 1: SMYD3 is upregulated in endometrial cancer and associated with tumor progression. | Oncogenesis

Fig. 1: SMYD3 is upregulated in endometrial cancer and associated with tumor progression.

From: SMYD3 promotes endometrial cancer through epigenetic regulation of LIG4/XRCC4/XLF complex in non-homologous end joining repair

Fig. 1

A, B The SMYD3 expression levels in para-tumor and tumor of EC tissues were measured by qRT-PCR (A) and Western blot (B), SMYD3-1, SMYD3-2 represented two different primers for human SMYD3. n = 10 for qRT-PCR C Immunohistochemistry of SMYD3 expression in para-tumor and tumor of EC tissues at different pathologic categories; scale bar, 60 μm. D The relative mRNA expression of SMYD3 in normal endometrial tissues and endometrial cancer tissues from the TCGA cohort using GEPIA 2 (http://gepia2.cancer-pku.cn/). E SMYD3 expression levels in different histological subtypes of EC with data from the TCGA database using UALCAN (http://ualcan.path.uab.edu/). F SMYD3 alterations in patients with EC tissues in the TCGA database using cBioPortal (https://www.cbioportal.org/). G Immunohistochemistry tissue microarrays showed SMYD3 expression level in para-tumor tissue and EC G1-G3 tissues. n = 18 for EC G1, n = 25 for EC G2, n = 14 for EC G3. Scale bar, 100 μm for ×10; 30 μm for ×40. H Immunohistochemistry of SMYD3 expression in the uteri of 30-week-old Pten knockout and Pten wild-type mice. Scale bar, 100 μm for ×10; 30 μm for ×40.

Back to article page